Eric A. Hoffman, PhD
Professor
Biography
Dr. Hoffman’s research is driven by questions pertaining to lung physiology, and by the development of imaging software and equipment designed specifically for the study of these questions. He uses single and multi-spectral multidetector row spiral CT imaging methodology to objectively follow human lung pathology and pathophysiology, with a particular emphasis on lung diseases involving inflammation. His expertise has facilitated the evaluation of lung pathology and bacterial clearance in animal models of CF.
| NIH-NHLBI/ 1T32HL144461 | Iowa Lung Imaging Training Program |
| NIH-NHLBI /R01HL169765 | Dynamic Imaging of Lung Ventilation and Perfusion Using Ct and MRI |
| NIH-NHLBI /U24HL138999 | Integrated Analysis of Microbial and Genomic data in Obstructive Lung Disease (I AM GOLD) Study |
| NIH-NHLBI /R01HL144718 | Understanding the Origins of Early COPD |
| NIH-NHLBI /R01HL155576 | Metal Exposure and Subclinical Lung Disease in Adult E-cigarette Users |
| NIH-NHLBI /R01HL157634 | COVID-19 Lung Microvascular and Parenchymal Sequelae (Lung-MaPS) |
| NIH-NHLBI /R01HL155816 | Airway Tree Subtyping on Large Cohorts of CT Images for COPD Risk |
| NIH-NCI /R01CA267820 | Lung cancer screening efficacy enhanced through radiomic and epigenetic biomarkers |
NIH-NHLBI/ UG3 HL154944 | 1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial |
| NIH-NHLBI /R01HL077612 | Precision phenotyping of emphysema in the elderly: the MESA Lung Study |
| NIH-NHLBI /R01HL155293 | Accuracy and Precision in CT Quantification of COPD Through Virtual Imaging Trials |
| NIH-NHLBI /R01HL164758 | Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung Disease |
| NIH-NCI /R01HL168116 | Learning and Subtyping of Post-COVID-19 Lung Progression Phenotypes |